By Dave Sebastian


Gilead Sciences Inc. said a comparison of a late-stage remdesivir trial with real-world treatment of patients with severe Covid-19 found that the drug suggests clinical recovery and a 62% reduction in mortality risk.

The Food and Drug Administration has authorized remdesivir for emergency use for the treatment of severe Covid-19, though it hasn't established the drug's safety and efficacy. Several U.S. states are seeing a resurgence in the disease caused by the new coronavirus as the race to develop Covid-19 vaccines and treatments continues.

About three-quarters of patients treated with remdesivir recovered by the second week, compared with 59% of patients who received standard care, Gilead said. The death rate of remdesivir-treated patients was 7.6% on Day 14, while the rate among patients who didn't take remdesivir was 12.5%, the company said.

The company said patients of traditionally marginalized racial and ethnic subgroups treated with remdesivir had similar outcomes as the overall patient population.

Gilead said 83% of pediatric patients and 92% of pregnant and postpartum women in the study recovered by the 28th day of treatment.

The Phase 3 study involved 312 patients and a separate cohort of 818 patients who received standard care in the same time period, Gilead said. Those patients were mostly located in North America, with others in Europe and Asia.

The comparative study adds to the previous National Institute Allergy and Infectious Disease study, which found that remdesivir-taking patients had a lower death rate compared with those who didn't take the drug. The NIAID study didn't reach statistical significance.

Gilead late last month said it will charge U.S. hospitals $3,120 for a typical patient using remdesivir. The U.S. has been distributing remdesivir donated by Gilead since the drug was authorized for emergency use in May.


Write to Dave Sebastian at


(END) Dow Jones Newswires

July 10, 2020 09:12 ET (13:12 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Gilead Sciences Charts.